References
- Litovitz T. L., Holm K. C., Clancy C., Schmitz B. F., Clark L. R., Oderda G. M. 1992 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1993; 11: 494–555
- Berkovitch M., Matsui D., Lamm S. H., Rosa F., Koren G. Recent increases in numbers and risk of fatalities in young children ingesting iron preparation. Vet Hum Toxicol 1994; 36: 53–55
- Engle J. P., Polin K. S., Stile I. L. Acute iron intoxication: treatment controversies. Drug Intell Clin Pharm 1987; 21: 153–159
- Tenenbein M. Inefftcacy of gastric emptying procedures. J Emerg Med 1985; 3: 133–136
- Czajka P. A., Konrad J. D., Duffy J. P. Iron poisoning: an in vitro comparison of bicarbonate and phosphate lavage solutions. J Pediatr 1981; 98: 491–494
- Dean B. S., Krenzelok E. P. In vivo effectiveness of oral complexation agents in the management of iron poisoning. J Toxicol Clin Toxicol 1987; 25: 221–230
- Proudfoot A. T., Simpson D., Dyson E. H. Management of acute iron poisoning. Med Toxicol 1986; 1: 83–100
- Olivieri N. F., Koren G., Hermann C., et al. Comparison of oral iron chelator LI and desferoxamine in iron‐loaded patients. Lancet 1990; 336: 1275–1279
- Olivieri N. F., Brittenham G. M., Matsui D., et al. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918–922
- Kontoghiorghes G. J., Sheppard L. Simple synthesis of the potent iron chelators l‐alkyl‐3‐hydroxy‐2‐methyl pyrid‐4‐ones. Inorganica Chim Acta 1989; L11–L12
- Klein J., Damani L. A., Chung D., Epemoulu O., Olivieri N., Koren G. A high performance liquid chromatographic method for the measurement of the iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one in human plasma. Ther Drug Monit 1991; 13: 51–54
- Tenenbein M., Kowalski S., Sienko A., Bowden D. H., Adamson I. Y. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339: 699–701